# Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder

> **NCT00836381** · PHASE4 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 56 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Tolterodine extended-release (ER) 4mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00836381
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2013-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00836381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00836381, "Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00836381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*